User login
Highlights in Early-Stage Non–Small Cell Lung Cancer From ASCO 2022
Highlights in early-stage non–small lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting are discussed by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California.
He opens with a post hoc analysis of CheckMate 816, which showed that achieving a pathologic complete response with adjuvant nivolumab plus chemotherapy was highly associated with improved event-free survival.
Next, Dr West reports on early results from the NADIM II trial, which confirmed the superiority of neoadjuvant nivolumab plus chemotherapy in resectable stage IIIa NSCLC, as well as the need for careful patient selection.
He moves on to describe the neoSCORE study, which compared two vs three cycles of neoadjuvant sintilimab plus chemotherapy, with the latter achieving a markedly higher major pathologic response rate.
Dr West next examines two interventional studies, starting with an analysis of the SEER database, which showed that addition of radiation therapy to neoadjuvant chemotherapy does not offer a benefit. He ends with a Veterans Affairs study underlining the importance of surgical quality as a predictor of patient outcomes.
--
Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California
Howard (Jack) West, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lily; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda
Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck
Highlights in early-stage non–small lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting are discussed by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California.
He opens with a post hoc analysis of CheckMate 816, which showed that achieving a pathologic complete response with adjuvant nivolumab plus chemotherapy was highly associated with improved event-free survival.
Next, Dr West reports on early results from the NADIM II trial, which confirmed the superiority of neoadjuvant nivolumab plus chemotherapy in resectable stage IIIa NSCLC, as well as the need for careful patient selection.
He moves on to describe the neoSCORE study, which compared two vs three cycles of neoadjuvant sintilimab plus chemotherapy, with the latter achieving a markedly higher major pathologic response rate.
Dr West next examines two interventional studies, starting with an analysis of the SEER database, which showed that addition of radiation therapy to neoadjuvant chemotherapy does not offer a benefit. He ends with a Veterans Affairs study underlining the importance of surgical quality as a predictor of patient outcomes.
--
Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California
Howard (Jack) West, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lily; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda
Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck
Highlights in early-stage non–small lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting are discussed by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California.
He opens with a post hoc analysis of CheckMate 816, which showed that achieving a pathologic complete response with adjuvant nivolumab plus chemotherapy was highly associated with improved event-free survival.
Next, Dr West reports on early results from the NADIM II trial, which confirmed the superiority of neoadjuvant nivolumab plus chemotherapy in resectable stage IIIa NSCLC, as well as the need for careful patient selection.
He moves on to describe the neoSCORE study, which compared two vs three cycles of neoadjuvant sintilimab plus chemotherapy, with the latter achieving a markedly higher major pathologic response rate.
Dr West next examines two interventional studies, starting with an analysis of the SEER database, which showed that addition of radiation therapy to neoadjuvant chemotherapy does not offer a benefit. He ends with a Veterans Affairs study underlining the importance of surgical quality as a predictor of patient outcomes.
--
Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California
Howard (Jack) West, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lily; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda
Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck
